|
|
 |
|
Viewing report
|
|
|
|
U.S. Peripheral Vascular Stent and Stent Grafts Markets
Frost & Sullivan, July 2006
This Frost & Sullivan research service entitled U.S. Peripheral Vascular Stent and Stent Grafts Market provides an overview of the trends and technologies that have shaped market revenue, market share, and implantation rates in the individual segments of the market. In this research, Frost & Sullivans expert analysts thoroughly examine the following markets: Aortic Aneurysms Grafts, Renal, Iliac, and Biliary stents, in addition to stents used in the lower extremity, including foropopliteal arteries and below the leg.
Market Sector
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis:
- Cardiovascular Devices
- Stents
Technologies
The following technologies are covered in this research:
- Self Expanding Stents
- Bioadsorbable
- Rapid Exchange
- Microcoils
- Liquid Embolics
Market Overview
Due to the plethora of devices with similar features vying for the market, being able to develop a robust technologically advanced product line will be critical to improving the chance a device witnesses high levels of success upon launch.
In the peripheral stent market, the development of next generation technology such as drug eluting capabilities, in situ stent control or bioadsorbable device, each technological feature has a significant benefit to reducing the risk of restenosis and improving the ease of implantation. Developing and launching a device that fails to offer a significant benefit over competing devices, forces that device to compete against a high degree of negative market challenges. Firms need to make themselves aware of the features that will best serve the market six to seven years down the line, when those products would have completed regulatory approval and be ready for market launch.
Being able to control the length of a stent in-situ for lesion sites that vary to the degree femoral occlusions do, will have a marked advantage over having to estimate the lesion size before hand. Bio-adsorbable devices also pose an obvious longterm advantage, in that the stent dissolves away after its usefulness. Standard metallic stents after the length of their intended use, actually are a risk factor for leading to vessel occlusion. Among those features, optimization of future product lines will be a major advantage to future market competitiveness.
Stenting and grafts are increasingly transitioning into the gold standard for combating peripheral vascular diseases (PVD). An underserved market with high rates of disability and morbidity represents a significant market opportunity for market participants to develop and launch novel medical stents customized for the intricacies of the peripheral vasculature. The long term clinical
success rates, in addition to the titanic revenue streams generated by the coronary stent market have sparked significant interest in their sister devices.
|
|
|
|
